Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INBS 
Intelligent Bio Solutions Inc. (INBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: INBS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.12% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.82M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 4.59 | 52 Weeks Range 1.10 - 3.00 | Updated Date 08/29/2025 |
52 Weeks Range 1.10 - 3.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-15 | When - | Estimate 0.08 | Actual -0.44 |
Profitability
Profit Margin - | Operating Margin (TTM) -341.46% |
Management Effectiveness
Return on Assets (TTM) -59.15% | Return on Equity (TTM) -192.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14077496 | Price to Sales(TTM) 4.85 |
Enterprise Value 14077496 | Price to Sales(TTM) 4.85 | ||
Enterprise Value to Revenue 4.61 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 8979150 | Shares Floating 8261179 |
Shares Outstanding 8979150 | Shares Floating 8261179 | ||
Percent Insiders 1.05 | Percent Institutions 7.99 |
Upturn AI SWOT
Intelligent Bio Solutions Inc.
Company Overview
History and Background
Intelligent Bio Solutions Inc. (IBS) focuses on developing and commercializing rapid, point-of-care diagnostics and drug testing solutions. Founded to leverage innovative biosensor technology, the company aims to address critical needs in various industries, including workplace safety, law enforcement, and healthcare.
Core Business Areas
- Drug Screening Solutions: Develops and commercializes rapid, point-of-care drug screening devices that provide results within minutes. These devices are used for workplace drug testing, law enforcement, and other applications.
Leadership and Structure
The leadership team consists of experienced executives in the diagnostics and healthcare industries. Organizational structure typically involves departments for research and development, manufacturing, sales and marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Intelligent Bio Solutions Drug Screening Device: A rapid, point-of-care drug screening device. Market share is developing as they gain traction. Competitors include Abbott (ABT), Thermo Fisher Scientific (TMO), and Roche (RHHBY).
Market Dynamics
Industry Overview
The point-of-care diagnostics and drug testing market is growing due to increasing demand for rapid, on-site testing. Factors driving growth include rising drug abuse rates, increasing workplace safety regulations, and technological advancements in biosensor technology.
Positioning
Intelligent Bio Solutions Inc. is positioning itself as a provider of innovative and user-friendly drug screening solutions. Competitive advantages may include speed, accuracy, and ease of use.
Total Addressable Market (TAM)
The global point-of-care diagnostics market is substantial, estimated in the tens of billions of dollars. IBS is targeting a portion of this market with its drug screening solutions and is positioned to grow as adoption increases.
Upturn SWOT Analysis
Strengths
- Innovative biosensor technology
- Rapid, point-of-care testing capabilities
- Focus on drug screening solutions
Weaknesses
- Limited market share
- Dependence on key customers
- Financial constraints
Opportunities
- Expanding into new markets
- Developing new products
- Partnering with distributors
Threats
- Competition from established players
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- ABT
- TMO
- RHHBY
Competitive Landscape
Intelligent Bio Solutions Inc. faces intense competition from established players with significant market share. Its advantages lie in its innovative technology, while disadvantages include limited resources and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available in the current context. Further financial research is required to determine past growth patterns.
Future Projections: Future growth projections are unavailable without analyst estimates and financial models. Further research is needed.
Recent Initiatives: Information on recent strategic initiatives is limited in the provided context. Further research is required.
Summary
Intelligent Bio Solutions Inc. is a developing company in the point-of-care diagnostics market. It has innovative biosensor technology and a focus on drug screening solutions. However, it faces strong competition and needs to expand market share and improve its financial position. Its success depends on successful commercialization and adaptation to regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Publicly available information
Disclaimers:
This analysis is based on limited information and subject to change. Market share data is approximate and may vary based on sources. Investment decisions should be based on thorough due diligence and professional advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intelligent Bio Solutions Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-23 | President & CEO Mr. Harry Simeonidis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53 | Website https://ibs.inc |
Full time employees 53 | Website https://ibs.inc | ||
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.